Results of Metastatic Colorectal Cancer Study Released
By MedImaging International staff writers Posted on 11 Jul 2017 |
Image: Researchers have found that adding SIRT to chemotherapy may boost colorectal cancer survival (Photo courtesy of MNT).
The results of a colorectal cancer study that compared standard first-line chemotherapy alone, and the same chemotherapy with Selective Internal Radiation Therapy (SIRT) treatment have been released.
The researchers reviewed the overall survival of the 1,103 patients who took part in the study. All patients had colorectal cancer that had spread to the liver. The patients were randomized to receive either only chemotherapy, or chemotherapy with SIRT radioembolization using SIR-Spheres Y-90 resin microspheres.
The results of the FOXFIRE Combined Analysis study were presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) by researchers from the University College London Cancer Institute (UCL; London, UK).
The patients had a median age of 63 years and had all been diagnosed with unresectable metastatic Colorectal Cancer (mCRC). The cancer had either metastasized to only the liver, or several additional parts of the body. The results did not show any significant difference in Overall Survival (OS) for the two groups, however an exploratory subgroup analysis of the FOXFIRE, SIRFLOX and FOXFIRE Global study did show that adding Y-90 resin microspheres to first-line chemotherapy for mCRC could increase OS in patients with right-sided primary colon tumors.
Co-principal investigator of the study, Professor Ricky Sharma, said, "Our analysis did not meet its primary endpoint of an overall survival (OS) benefit for patients treated with SIRT plus first-line chemotherapy compared to patients treated with chemotherapy alone. Nonetheless, I believe this study has significantly enriched scientific understanding of the role of SIRT in the management of metastatic colorectal cancer, particularly in the liver. Finding more effective treatments remains a critical issue for these patients. Following further validation, this unexpected finding may prove to be clinically meaningful as patients with right-sided primary colon tumors represent more than a third (35–38%) of all colon cancer patients."
Related Links:
University College London Cancer Institute
The researchers reviewed the overall survival of the 1,103 patients who took part in the study. All patients had colorectal cancer that had spread to the liver. The patients were randomized to receive either only chemotherapy, or chemotherapy with SIRT radioembolization using SIR-Spheres Y-90 resin microspheres.
The results of the FOXFIRE Combined Analysis study were presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) by researchers from the University College London Cancer Institute (UCL; London, UK).
The patients had a median age of 63 years and had all been diagnosed with unresectable metastatic Colorectal Cancer (mCRC). The cancer had either metastasized to only the liver, or several additional parts of the body. The results did not show any significant difference in Overall Survival (OS) for the two groups, however an exploratory subgroup analysis of the FOXFIRE, SIRFLOX and FOXFIRE Global study did show that adding Y-90 resin microspheres to first-line chemotherapy for mCRC could increase OS in patients with right-sided primary colon tumors.
Co-principal investigator of the study, Professor Ricky Sharma, said, "Our analysis did not meet its primary endpoint of an overall survival (OS) benefit for patients treated with SIRT plus first-line chemotherapy compared to patients treated with chemotherapy alone. Nonetheless, I believe this study has significantly enriched scientific understanding of the role of SIRT in the management of metastatic colorectal cancer, particularly in the liver. Finding more effective treatments remains a critical issue for these patients. Following further validation, this unexpected finding may prove to be clinically meaningful as patients with right-sided primary colon tumors represent more than a third (35–38%) of all colon cancer patients."
Related Links:
University College London Cancer Institute
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection